Oct 17, 2023 / 03:00PM GMT
Operator
Good day, everyone, and welcome to the Mural Oncology Investor Call. Today's call is being recorded. At this time, I'd like to turn the call over to Dave Bora. Please go ahead.
Unidentified Company Representative -
Hello, and welcome to Mural Oncology's investor presentation. I'm Dave Bora, SVP of IR and Corporate Affairs from Mural, and I'm pleased to be joined by CEO, Caroline Loew VP Clinical Research Oncology, Jessicca Rege; Director of R&D, Josh Heiber and Principal Scientist, Mark Whitmore. We look forward to telling you more about Mural is protein engineering capabilities, how our lead asset in nemvaleukin differs from other IL-2 approaches, now are exciting candidates in our pipeline. We'll leave time at the end for Q&A as well.
Today, we'll be making forward-looking statements about our business, including our pipeline assets. Just to note, of course, that this is an inherently risky business, and we do our best to articulate the risk that we face but for more information we'd always point you to our SEC disclosures.
Here's a look at
Alkermes Plc Mural Oncology Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers